

JANUS HENDERSON CAPITAL FUNDS PLC – JANUS HENDERSON
GLOBAL LIFE SCIENCES FUND

I2 USD ISIN IE0002141913

Investment objective


The Fund aims to provide capital growth over the long term. The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.

Performance (%)

Returns	Cumulative			Annualised				
	1 Month	3 Month	YTD	1 Year	3 Year	5 Year	10 Year	Since inception
I2 USD (Net) with sales charge	-0.41	6.13	6.13	14.60	5.84	10.00	10.13	8.15
Index	2.35	7.47	7.47	13.32	7.85	10.33	9.18	7.79
Sector	1.45	4.27	4.27	7.22	-0.28	5.59	6.23	6.21
I2 USD (Net)	1.63	8.30	8.30	16.94	6.55	10.44	10.35	8.24

Cumulative growth - USD

31 Mar 2014 — 31 Mar 2024



Calendar year

	YTD at Q1 2024	2023	2022	2021	2020	2019
I2 USD (Net)	8.30	6.32	-3.59	5.60	24.37	28.04
Index	7.47	3.76	-5.41	19.80	13.52	23.24
Sector	4.27	2.67	-13.91	7.12	20.53	21.80

Performance is net of fees, with gross income reinvested. Performance figures of less than 1 year are not annualised. Source: at 31/03/24. © 2024 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. **Past performance does not predict future returns. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.** For sales charge information, refer to Additional information on page 3. Please note index returns are net of tax.

Fund details

Inception date	31 March 2000
Total net assets	\$4.08bn
Asset class	Equities
Domicile	Ireland
Structure	Irish Investment Company
Base currency	USD
Index	MSCI World Health Care Index
Morningstar sector	Sector Equity Healthcare
SFDR category	Article 8

In accordance with the Sustainable Finance Disclosure Regulation, the Fund is classified as Article 8 and promotes, among other characteristics, environmental and/or social characteristics, and invests in companies with good governance practices.

Share class information

Inception date	31 March 2000
NAV (USD)	66.83
Distribution type	Accumulation
Currency	USD
Minimum initial investment	1,000,000

Portfolio management

Andy Acker, CFA	Manager since 2007
Daniel Lyons, Ph.D., CFA	Manager since 2023

Ratings

Overall Morningstar Rating™	★★★★★
As of 31/03/2024	

For more information, refer to page 3.

Characteristics

Number of holdings: Equity issues	120
Annual turnover (1yr trailing)	31.18%
Weighted average market cap	176.46bn
Price-to-book ratio	5.20
Price-to-earnings ratio	20.28

Risk statistics (3 years)

	Fund	Index
Beta	0.99	—
Standard deviation	15.24	14.17
Sharpe ratio	0.24	0.35

Top holdings (%)

	Fund
Eli Lilly & Co	7.08
UnitedHealth Group Inc	5.87
Novo Nordisk A/S	5.13
Merck & Co Inc	3.64
AstraZeneca PLC	3.57
AbbVie Inc	3.36
Sanofi SA	2.48
Boston Scientific Corp	2.30
Vertex Pharmaceuticals Inc	2.30
Abbott Laboratories	2.26
Total	37.99

References made to individual securities should not constitute or form part of any offer or solicitation to issue, securities mentioned in the report.

Market capitalisation of equity holdings (%)

	Fund	Index
Over \$100B	54.25	68.66
\$50B to \$100B	4.42	10.19
\$10B to \$50B	17.44	19.52
\$5B to \$10B	7.21	1.41
\$1B to \$5B	13.60	0.09
\$500M to \$1B	0.73	—
\$250M to \$500M	0.10	—
N/A	1.63	0.13

Sector allocation (%)

	Fund	Index
Biotechnology	32.81	13.68
Pharmaceuticals	30.44	41.79
Health Care Equipment	14.25	16.11
Managed Health Care	9.53	8.83
Life Sciences Tools & Services	5.61	9.58
Health Care Supplies	2.94	2.78
Health Care Distributors	1.63	2.03
Health Care Facilities	1.31	1.09
Health Care Services	0.68	3.57
Application Software	0.11	—

Top countries/regions (%)

	Fund	Index
United States	78.47	72.58
Denmark	6.56	5.88
United Kingdom	3.57	4.02
Switzerland	3.34	6.68
France	2.48	2.63
Netherlands	1.60	0.20
Japan	1.56	3.89
China	1.25	—
Ireland	0.51	—
Korea, Republic Of	0.04	—

Regions (%)

	Fund	Index
North America	78.47	72.58
Europe	18.06	21.63
Japan	1.56	3.89
Asia/Pacific Ex Japan	1.29	1.70

Codes

ISIN	IE0002141913
Bloomberg	JANGLII
Cusip	G50110207
SEDOL	0214191

Fees & charges (%)

Maximum initial sales charge	2.00
Annual management charge (AMC)	1.50
Total expense ratio (TER)	1.58

Fund charges will impact the value of your investment. In particular, the ongoing charges applicable to each fund will dilute investment performance, particularly over time. For further explanation of charges please visit our Fund Charges page at www.janushenderson.com. Under some circumstances initial charges may apply. Please refer to the Prospectus for more details.

Additional fund information

Tax assumptions and reliefs depend upon an investor's particular circumstances and may be subject to change. As of 31 January 2023, Daniel Lyons Ph.D., CFA also manages this fund. Please note: due to rounding the figures in the holdings breakdowns may not add up to 100%. This is an Irish Investment Company regulated by the Central Bank of Ireland. Information relating to other currencies and fee structure can be found in the fund prospectus. Note that any differences among portfolio securities currencies, share class currencies and costs to be paid or represented in currencies other than your home currency will expose you to currency risk. Costs and returns may increase or decrease as a result of currency and exchange rate fluctuations. To obtain our prospectus and any additional information please visit our website on: www.janushenderson.com. A short-term trading fee may be applied upon exiting the fund as per the prospectus. Investment into the fund will acquire units/shares of the fund itself and not the underlying assets owned by the fund. Cash balances and exposures are based on settled and unsettled trades as at the reporting date. Performance with sales charge assume 2% initial sales charge/front-end load (FEL) applied. All ongoing charges stated are as per latest published report and accounts. Where the ongoing charges exceed the target outperformance relative to the benchmark the return is likely to be below the benchmark return, even when the Fund's outperformance target (before the deduction of charges) has been achieved. For funds which charge performance fees, investors should note that the total expense ratio includes the performance fees crystallised for the preceding performance period.

Fund specific risks

When the Fund, or a share/unit class, seeks to mitigate exchange rate movements of a currency relative to the base currency (hedge), the hedging strategy itself may positively or negatively impact the value of the Fund due to differences in short-term interest rates between the currencies. The Fund could lose money if a counterparty with which the Fund trades becomes unwilling or unable to meet its obligations, or as a result of failure or delay in operational processes or the failure of a third party provider. Shares/Units can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result. Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses. If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified. The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events. The Fund may use derivatives to help achieve its investment objective. This can result in leverage (higher levels of debt), which can magnify an investment outcome. Gains or losses to the Fund may therefore be greater than the cost of the derivative. Derivatives also introduce other risks, in particular, that a derivative counterparty may not meet its contractual obligations. If the Fund holds assets in currencies other than the base currency of the Fund, or you invest in a share/unit class of a different currency to the Fund (unless hedged, i.e. mitigated by taking an offsetting position in a related security), the value of your investment may be impacted by changes in exchange rates. Securities within the Fund could become hard to value or to sell at a desired time and price, especially in extreme market conditions when asset prices may be falling, increasing the risk of investment losses.

Source for fund ratings/awards

Overall Morningstar Rating™ is a measure of a fund's risk-adjusted return, relative to similar funds. Fund share classes are rated from 1 to 5 stars, with the best performers receiving 5 stars and the worst performers receiving a single star. Overall Morningstar Rating™ is shown for Janus Henderson share classes achieving a rating of 4 or 5. Ratings should not be taken as a recommendation. For more detailed information about Morningstar Ratings, including its methodology, please go to www.global.morningstar.com/managerdisclosures.

Glossary

Beta

Beta measures how a fund or security moves in relationship to the overall market. A market has a beta of 1. If the fund/security's beta is more than 1, it moves more than the market, while a beta lower than 1 means it moves to a lesser extent than the market. A negative beta could mean the fund/security moves in the opposite direction to the market.

Price-to-book (P/B) ratio

A financial ratio used to value a company's shares. It is calculated by dividing a company's market value (share price) by the book value of its equity (value of the company's assets on its balance sheet). A P/B value <1 can indicate a potentially undervalued company or a declining business. The higher the P/B ratio, the higher the premium the market is willing to pay for the company above the book (balance sheet) value of its assets.

Price-to-earnings (P/E) ratio

A popular ratio used to value a company's shares, compared to other stocks, or a benchmark index. It is calculated by dividing the current share price by its earnings per share.

Sharpe ratio

This measures a portfolio's risk-adjusted performance. A high Sharpe ratio indicates a better risk-adjusted return. The ratio is designed to measure how far a portfolio's return can be attributed to fund manager skill as opposed to excessive risk taking.

Standard deviation

A statistic that measures the variation or dispersion of a set of values/data. A low standard deviation shows the values tend to be close to the mean while a high standard deviation indicates the values are more spread out. In terms of valuing investments, standard deviation can provide a gauge of the historical volatility of an investment.

Weighted average market cap

The average market capitalisation of a holding, weighted by the size of that position in a portfolio or index.

Issued in Singapore by Janus Henderson Investors (Singapore) Limited, licensed and regulated by the Monetary Authority of Singapore, Company Registration No. 199700782N. **This advertisement has not been reviewed by the Monetary Authority of Singapore.** The content herein is produced for information purposes only and does not constitute investment advice or as an offer to sell, buy or a recommendation for any security. Janus Henderson Investors is not responsible for any unlawful distribution of this document to any third parties, in whole or in part, and do not make any warranties with regards to the results obtained from its use. In preparing this document, Janus Henderson Investors has reasonable belief to rely upon the accuracy and completeness of all information available from public sources. **Past performance does not predict future returns. Investing involves risk, including the possible loss of principal and fluctuation of value.** The Fund may employ investment techniques and instruments for investment purposes, such as trading in futures, options and swaps and other financial derivative instruments. This document has been prepared by Janus Henderson Investors (Singapore) Limited, the Singapore Representative of the Fund. The Fund is distributed by authorised distributors. The prospectus and Product Highlights Sheet ("PHS") of the Fund are available and may be obtained from the Singapore Representative's office and the authorized distributors' offices. Investors should read the prospectus and PHS before deciding whether to invest in the shares of the Fund. Investors are warned that they should only make their investments based on the most recent offering documents which contains information about fees, expenses and risks, which is available from appointed intermediaries, and which should be read carefully. An investment in the Fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost. Investors are advised to consult your intermediary who will give you advice on the product suitability and help you determine how your investment would be consistent with your own investment objectives. The investment decisions are yours and an investment in the Fund may not be suitable for everyone. If in doubt, please contact your intermediary for clarification. Portfolio holdings are subject to change without notice. © 2024 Morningstar. All Rights Reserved. CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute. Janus Henderson is a trademark of Janus Henderson Group plc or one of its subsidiary entities. ©Janus Henderson Group plc.